Stavros P. Derdas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stavros P. Derdas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Grigoris Risvas
Department of Dietetics, School of Health, Aegean College, 10564 Athens, Greece
3 shared publications Demetrios Spandidos
Laboratory of Clinical Virology, Medical School, University of Crete, 70013 Heraklion, Greece
1 shared publication- Dimitra Panagiotidi
Department of Dietetics, School of Health, Aegean College, 10564 Athens, Greece
1 shared publication - Olga Chouliara
Department of Dietetics, School of Health, Aegean College, 10564 Athens, Greece
1 shared publication - Paraskevi Apeiranthiti
Department of Dietetics, School of Health, Aegean College, 10564 Athens, Greece
1 shared publication - Sofjana Gushi
Molecular Diagnostics Laboratory, KARYO Ltd., 54623 Thessaloniki, Greece
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Preprints.org
HPV-Associated Epigenetic Reprogramming in Oropharyngeal Squamous Cell Carcinoma: Molecular Mechanisms, Circulating Biomarkers and Clinical Translation
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has become the dominant form of oropharyngeal cancer in many high-income countries and is now recognised as a biologically and clinically distinct entity with markedly better survival than its tobacco-related counterpart. Beyond the canonical inactivation of p53 and pRb by the viral oncoproteins E6 and E7, HPV profoundly remodels the host and viral epigenomes. HPV-positive tumours display a hypermethylated landscape, including a CpG island methylator-like phenotype that targets Polycomb repressive complex 2 genes, alongside altered histone-modifying activity, chromatin remodelling and deregulated non-coding RNA networks. Methylation of the viral genome itself, particularly of the upstream regulatory region and E2 binding sites, tracks with integration and oncogene expression. These changes shape the tumour immune microenvironment and treatment response. They also leave traces in the circulation: circulating tumour HPV DNA, methylated cell-free DNA and extracellular-vesicle microRNAs are emerging as tools for diagnosis, risk stratification and post-treatment surveillance. This review summarises current knowledge of HPV-driven epi-genetic reprogramming in OPSCC, evaluates the analytical and clinical validity of epigenetic and viral liquid-biopsy biomarkers, and discusses their translation into treatment de-escalation, epigenetic therapy, immunotherapy com-binations and nutri-epigenetic modulation.
- 18 November 2026
- Published by MDPI AG in Preprints.org
Open AccessHPV-Associated Epigenetic Reprogramming in Oropharyngeal Squamous Cell Carcinoma: Molecular Mechanisms, Circulating Biomarkers and Clinical Translation
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has become the dominant form of oropharyngeal cancer in many high-income countries and is now recognised as a biologically and clinically distinct entity with markedly better survival than its tobacco-related counterpart. Beyond the canonical inactivation of p53 and pRb by the viral oncoproteins E6 and E7, HPV profoundly remodels the host and viral epigenomes. HPV-positive tumours display a hypermethylated landscape, including a CpG island methylator-like phenotype that targets Polycomb repressive complex 2 genes, alongside altered histone-modifying activity, chromatin remodelling and deregulated non-coding RNA networks. Methylation of the viral genome itself, particularly of the upstream regulatory region and E2 binding sites, tracks with integration and oncogene expression. These changes shape the tumour immune microenvironment and treatment response. They also leave traces in the circulation: circulating tumour HPV DNA, methylated cell-free DNA and extracellular-vesicle microRNAs are emerging as tools for diagnosis, risk stratification and post-treatment surveillance. This review summarises current knowledge of HPV-driven epi-genetic reprogramming in OPSCC, evaluates the analytical and clinical validity of epigenetic and viral liquid-biopsy biomarkers, and discusses their translation into treatment de-escalation, epigenetic therapy, immunotherapy com-binations and nutri-epigenetic modulation.
- Open Access
- 3 November 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (6) , 1-8
Pancreatic cancer biomarkers and diagnostic tools (Review)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by late presentation, early systemic dissemination and profound therapeutic resistance. Biomarkers are therefore required not only for early detection, but also for prognosis, treatment selection and longitudinal monitoring. The present review summarizes established and emerging PDAC biomarkers across genomics, epigenomics, transcriptomics, proteomics, metabolomics and liquid biopsy. Particular attention is given to predictive biomarkers for personalized systemic therapy, including homologous‑recombination repair defects associated with platinum sensitivity and eligibility for maintenance olaparib, as well as investigational markers of response to gemcitabine, fluoropyrimidines, irinotecan and oxaliplatin. The evolving role of companion diagnostics for germline BRCA1/2 variants and tumor‑agnostic alterations is also discussed. In addition, the present review discusses biomarkers associated with occult or distant metastasis, including circulating tumor DNA, circulating tumor cells, extracellular vesicles, the SMAD4 status and multi‑modal radiomic models. CA19‑9 remains the most commonly used serum marker; however, it is unsuitable for population screening and cannot independently establish diagnosis or metastatic risk. The majority of multi‑omics candidates remain at the discovery or retrospective‑validation stage. Their clinical translation requires analytically standardized assays, prospective validation in defined clinical settings and evidence that biomarker‑guided decisions improve patient outcomes.
- 3 November 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (6) , 1-8
Open AccessPancreatic cancer biomarkers and diagnostic tools (Review)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by late presentation, early systemic dissemination and profound therapeutic resistance. Biomarkers are therefore required not only for early detection, but also for prognosis, treatment selection and longitudinal monitoring. The present review summarizes established and emerging PDAC biomarkers across genomics, epigenomics, transcriptomics, proteomics, metabolomics and liquid biopsy. Particular attention is given to predictive biomarkers for personalized systemic therapy, including homologous‑recombination repair defects associated with platinum sensitivity and eligibility for maintenance olaparib, as well as investigational markers of response to gemcitabine, fluoropyrimidines, irinotecan and oxaliplatin. The evolving role of companion diagnostics for germline BRCA1/2 variants and tumor‑agnostic alterations is also discussed. In addition, the present review discusses biomarkers associated with occult or distant metastasis, including circulating tumor DNA, circulating tumor cells, extracellular vesicles, the SMAD4 status and multi‑modal radiomic models. CA19‑9 remains the most commonly used serum marker; however, it is unsuitable for population screening and cannot independently establish diagnosis or metastatic risk. The majority of multi‑omics candidates remain at the discovery or retrospective‑validation stage. Their clinical translation requires analytically standardized assays, prospective validation in defined clinical settings and evidence that biomarker‑guided decisions improve patient outcomes.
- Open Access
Nutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives
Cancer development is influenced not only by genetic alterations but also by epigenetic dysregulation driven by environmental and lifestyle factors, particularly diet. Nutrigenomics investigates how dietary components interact with the genome to influence gene expression, while nutritional epigenetics focuses on diet-induced modifications such as DNA methylation, histone modifications and non-coding RNA regulation. Increasing evidence indicates that bioactive dietary compounds can modulate epigenetic mechanisms involved in carcinogenesis, highlighting their potential role in cancer prevention. This narrative review synthesizes recent evidence, with emphasis on literature published between 2015 and 2025 and an updated search through September 2026 on the molecular interplay between diet, epigenetic regulation and cancer risk. We examine how key dietary factors—including methyl donors involved in one-carbon metabolism, polyphenols, short-chain fatty acids and omega-3 fatty acids—modulate epigenetic regulators such as DNA methyltransferases and histone deacetylases. Particular emphasis is placed on the emerging Nutrigenomics–Microbiome–Epigenome Axis, whereby microbiota-derived metabolites influence host chromatin architecture and gene expression pathways relevant to tumor suppression and inflammation. In addition, we discuss current evidence linking dietary patterns, including Mediterranean and Western diets, with distinct epigenomic signatures associated with cancer susceptibility. The review further explores the potential of epigenetic biomarkers and epigenome-wide association studies to support precision nutrition strategies for cancer prevention. Collectively, accumulating evidence suggests that diet-driven epigenetic plasticity may contribute to cancer prevention. However, the human evidence remains heterogeneous, and large, well-designed intervention studies with standardized epigenetic endpoints are required before mechanistic findings can be translated into clinically actionable precision nutrition strategies.
Open AccessNutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives
Cancer development is influenced not only by genetic alterations but also by epigenetic dysregulation driven by environmental and lifestyle factors, particularly diet. Nutrigenomics investigates how dietary components interact with the genome to influence gene expression, while nutritional epigenetics focuses on diet-induced modifications such as DNA methylation, histone modifications and non-coding RNA regulation. Increasing evidence indicates that bioactive dietary compounds can modulate epigenetic mechanisms involved in carcinogenesis, highlighting their potential role in cancer prevention. This narrative review synthesizes recent evidence, with emphasis on literature published between 2015 and 2025 and an updated search through September 2026 on the molecular interplay between diet, epigenetic regulation and cancer risk. We examine how key dietary factors—including methyl donors involved in one-carbon metabolism, polyphenols, short-chain fatty acids and omega-3 fatty acids—modulate epigenetic regulators such as DNA methyltransferases and histone deacetylases. Particular emphasis is placed on the emerging Nutrigenomics–Microbiome–Epigenome Axis, whereby microbiota-derived metabolites influence host chromatin architecture and gene expression pathways relevant to tumor suppression and inflammation. In addition, we discuss current evidence linking dietary patterns, including Mediterranean and Western diets, with distinct epigenomic signatures associated with cancer susceptibility. The review further explores the potential of epigenetic biomarkers and epigenome-wide association studies to support precision nutrition strategies for cancer prevention. Collectively, accumulating evidence suggests that diet-driven epigenetic plasticity may contribute to cancer prevention. However, the human evidence remains heterogeneous, and large, well-designed intervention studies with standardized epigenetic endpoints are required before mechanistic findings can be translated into clinically actionable precision nutrition strategies.
- Open Access
- 13 July 2026
- Published by MDPI AG in Preprints.org
Nutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives
Cancer development is influenced not only by genetic alterations but also by epigenetic dysregulation driven by environmental and lifestyle factors, particularly diet. Nutrigenomics investigates how dietary components interact with the genome to influence gene expression, while nutritional epigenetics focuses on diet-induced modifications such as DNA methylation, histone modifications and non-coding RNA regulation. Increasing evidence indicates that bioactive dietary compounds can modulate epigenetic mechanisms involved in carcinogenesis, highlighting their potential role in cancer prevention. This review synthesises recent evidence (2015–2025) on the molecular interplay between diet, epigenetic reg-ulation and cancer risk. We examine how key dietary factors—including methyl donors involved in one-carbon metabolism, polyphenols, short-chain fatty acids and omega-3 fatty acids—modulate epigenetic regulators such as DNA methyltransferases and histone deacetylases. Particular emphasis is placed on the emerging diet–microbiota–epigenome axis, whereby microbiota-derived metabolites influence host chromatin architecture and gene expression pathways relevant to tumour suppression and inflammation. In addition, we discuss current evidence linking dietary patterns, including Mediterranean and Western diets, with distinct epigenomic signatures associated with cancer susceptibility. The review further explores the potential of epigenetic biomarkers and epigenome-wide association studies to support precision nutrition strategies for cancer prevention. Collectively, accumulating data suggest that diet-driven epigenetic plasticity represents a promising avenue for cancer prevention. However, further large-scale human studies integrating multi-omics approaches are required to translate mechanistic insights into clinically applicable precision nutrition interventions.
- 13 July 2026
- Published by MDPI AG in Preprints.org
Open AccessNutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives
Cancer development is influenced not only by genetic alterations but also by epigenetic dysregulation driven by environmental and lifestyle factors, particularly diet. Nutrigenomics investigates how dietary components interact with the genome to influence gene expression, while nutritional epigenetics focuses on diet-induced modifications such as DNA methylation, histone modifications and non-coding RNA regulation. Increasing evidence indicates that bioactive dietary compounds can modulate epigenetic mechanisms involved in carcinogenesis, highlighting their potential role in cancer prevention. This review synthesises recent evidence (2015–2025) on the molecular interplay between diet, epigenetic reg-ulation and cancer risk. We examine how key dietary factors—including methyl donors involved in one-carbon metabolism, polyphenols, short-chain fatty acids and omega-3 fatty acids—modulate epigenetic regulators such as DNA methyltransferases and histone deacetylases. Particular emphasis is placed on the emerging diet–microbiota–epigenome axis, whereby microbiota-derived metabolites influence host chromatin architecture and gene expression pathways relevant to tumour suppression and inflammation. In addition, we discuss current evidence linking dietary patterns, including Mediterranean and Western diets, with distinct epigenomic signatures associated with cancer susceptibility. The review further explores the potential of epigenetic biomarkers and epigenome-wide association studies to support precision nutrition strategies for cancer prevention. Collectively, accumulating data suggest that diet-driven epigenetic plasticity represents a promising avenue for cancer prevention. However, further large-scale human studies integrating multi-omics approaches are required to translate mechanistic insights into clinically applicable precision nutrition interventions.
- Open Access
Addressing Childhood Malnutrition in Europe: Policy Approaches to Promote Healthy Eating in Young Children
Childhood malnutrition remains a pressing public health challenge in Europe, where stunting, wasting, and underweight coexist with rising rates of childhood overweight and obesity. This policy review provides a strategic roadmap for promoting healthy nutrition in early childhood by synthesizing WHO and EU guidance and proposing coordinated action across three time horizons. Short-term goals (1–3 years) include harmonizing food-based dietary guidelines, implementing universal nutrition screening in pediatric care, and strengthening breastfeeding-supportive environments. Mid-term priorities (3–7 years) focus on fiscal levers, such as sugar taxes and healthy food subsidies; reformulating children’s products; and embedding nutrition education within school curricula. Long-term strategies (7+ years) emphasize harmonized EU-wide monitoring systems, alignment of early-life nutrition with social protection policies, and sustained investment in research on the DOHaD. Through a unified, multisectoral strategy emphasizing early-life nutrition, equitable access to healthy foods, education, and robust regulation, Europe can effectively address the double burden of malnutrition and sustainably reduce childhood obesity.
Open AccessAddressing Childhood Malnutrition in Europe: Policy Approaches to Promote Healthy Eating in Young Children
Childhood malnutrition remains a pressing public health challenge in Europe, where stunting, wasting, and underweight coexist with rising rates of childhood overweight and obesity. This policy review provides a strategic roadmap for promoting healthy nutrition in early childhood by synthesizing WHO and EU guidance and proposing coordinated action across three time horizons. Short-term goals (1–3 years) include harmonizing food-based dietary guidelines, implementing universal nutrition screening in pediatric care, and strengthening breastfeeding-supportive environments. Mid-term priorities (3–7 years) focus on fiscal levers, such as sugar taxes and healthy food subsidies; reformulating children’s products; and embedding nutrition education within school curricula. Long-term strategies (7+ years) emphasize harmonized EU-wide monitoring systems, alignment of early-life nutrition with social protection policies, and sustained investment in research on the DOHaD. Through a unified, multisectoral strategy emphasizing early-life nutrition, equitable access to healthy foods, education, and robust regulation, Europe can effectively address the double burden of malnutrition and sustainably reduce childhood obesity.